Deep Apple Therapeutics, founded in 2022, is a U.S.-based company in the Biotechnology and Health and Wellness industries. Their mission, as encapsulated by their slogan, is "Accelerating drug discovery with structure-based large library virtual screening and deep learning models."
Their innovative approach leverages a combination of ensemble cryo-EM, deep learning, and proprietary Orchard.ai™ algorithms to explore receptor conformations, achieving rapid identification of novel small molecules targeting inflammatory, metabolic, and endocrine diseases. This structure-based, machine-learning driven drug discovery engine capitalizes on the founder's expertise in computational modeling and protein dynamics.
Most recently, Deep Apple Therapeutics secured a $52.00M Series A investment on 14 December 2023, led by Apple Tree Partners. This investment will further support their advancements in novel candidate development for well-validated therapeutic targets.